The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

In the U.S., the average lifetime risk of multiple myeloma is less than 1%. In 2025, the American Cancer Society estimates that 36,110 new cases of multiple myeloma will be diagnosed, affecting ...

Although commonly seen in elderly population, osteoporosis is increasingly being diagnosed in younger population nowadays.

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma ...

Multiple myeloma is the second most commonly diagnosed type of blood cancer (after lymphoma). But it’s still relatively uncommon. Around the world, there were about 180,000 new cases in 2022.

OAK BROOK, Ill. – New CT technology paired with artificial intelligence (AI)-based noise reduction offers superior detection of bone disease associated with multiple myeloma at lower radiation ...

They were followed to see how long it took for their multiple myeloma to progress, meaning that the cancer got worse. This measurement is called progression-free survival. The ages of people in ...

Multiple myeloma, a cancer of the cells in the bone marrow, is diagnosed in more than 35,000 people in the U.S. each year, according to the American Cancer Society.